NeuBase Therapeutics Inc (NBSE)
0.405
-0.01
(-1.72%)
USD |
NASDAQ |
May 03, 16:00
0.376
-0.03
(-7.16%)
After-Hours: 20:00
NeuBase Therapeutics Net Income (Quarterly): -1.821M for Sept. 30, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | -1.821M |
| June 30, 2023 | -3.447M |
| March 31, 2023 | -4.093M |
| December 31, 2022 | -4.369M |
| September 30, 2022 | -7.632M |
| June 30, 2022 | -8.492M |
| March 31, 2022 | -9.924M |
| December 31, 2021 | -7.729M |
| September 30, 2021 | -7.158M |
| June 30, 2021 | -8.663M |
| March 31, 2021 | -5.522M |
| December 31, 2020 | -4.066M |
| September 30, 2020 | -4.701M |
| June 30, 2020 | -3.800M |
| March 31, 2020 | -4.378M |
| December 31, 2019 | -4.506M |
| September 30, 2019 | -22.96M |
| June 30, 2019 | -1.133M |
| March 31, 2019 | -1.143M |
| December 31, 2018 | -0.8976M |
| September 30, 2018 | -6.356M |
| June 30, 2018 | -0.545M |
| March 31, 2018 | -2.185M |
| December 31, 2017 | -4.151M |
| September 30, 2017 | -5.244M |
| Date | Value |
|---|---|
| June 30, 2017 | -3.901M |
| March 31, 2017 | -7.690M |
| December 31, 2016 | -6.976M |
| September 30, 2016 | -6.636M |
| June 30, 2016 | -7.700M |
| March 31, 2016 | -5.285M |
| December 31, 2015 | -6.146M |
| September 30, 2015 | -3.910M |
| June 30, 2015 | -3.346M |
| March 31, 2015 | -3.400M |
| December 31, 2014 | -4.598M |
| September 30, 2014 | -3.090M |
| June 30, 2014 | -2.051M |
| March 31, 2014 | -1.968M |
| December 31, 2013 | -2.022M |
| September 30, 2013 | -1.803M |
| June 30, 2013 | -1.338M |
| March 31, 2013 | -0.2923M |
| December 31, 2012 | -2.218M |
| September 30, 2012 | 0.0674M |
| June 30, 2012 | -0.4608M |
| March 31, 2012 | -1.412M |
| December 31, 2011 | 0.3507M |
| September 30, 2011 | -1.358M |
| June 30, 2011 | -3.138M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-22.96M
Minimum
Sep 2019
-1.133M
Maximum
Jun 2019
-6.355M
Average
-4.603M
Median
Net Income (Quarterly) Benchmarks
| Ampio Pharmaceuticals Inc | -2.054M |
| Stoke Therapeutics Inc | -26.96M |
| ABVC BioPharma Inc | -3.111M |
| MAIA Biotechnology Inc | -6.257M |
| Aprea Therapeutics Inc | -3.443M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.591M |
| EPS Diluted (Quarterly) | -0.66 |
| Enterprise Value | -11.06M |
| Earnings Yield | -1.90K% |